DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Cortes JE, Baccarani M, Guilhot F. et al.
Phase III, randomized, open-label study
of daily imatinib mesylate 400 mg versus 800 mg in
patients with newly diagnosed, previously untreated chronic myeloid
leukemia in chronic phase using molecular end points: tyrosine kinase
inhibitor optimization and selectivity study.
J Clin Oncol 2010; 28: 424-430
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.